These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 31002457)
1. The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of "real world" practice in people with diabetes. Bengaluru Jayanna M; Robinson JG Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():17-27. PubMed ID: 31002457 [TBL] [Abstract][Full Text] [Related]
2. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice. Bruckert E; Ferrières J Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429 [TBL] [Abstract][Full Text] [Related]
3. Intensive statin therapy for Indians: Part-I. Benefits. Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339 [TBL] [Abstract][Full Text] [Related]
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
5. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377 [TBL] [Abstract][Full Text] [Related]
6. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Fabbri G; Maggioni AP Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394 [TBL] [Abstract][Full Text] [Related]
8. HDL-C: role as a risk modifier. Barter P Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280 [TBL] [Abstract][Full Text] [Related]
9. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775 [TBL] [Abstract][Full Text] [Related]
10. Nonstatin therapies for management of dyslipidemia: a review. Sando KR; Knight M Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799 [TBL] [Abstract][Full Text] [Related]
11. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Mora S; Ridker PM Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935 [TBL] [Abstract][Full Text] [Related]
13. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394 [TBL] [Abstract][Full Text] [Related]
14. Situational Analysis of Low-density Lipoprotein Cholesterol Control and the Use of Statin Therapy in Diabetes Patients Treated in Community Hospitals in Nanjing, China. Ouyang XJ; Zhang YQ; Chen JH; Li T; Lu TT; Bian RW Chin Med J (Engl); 2018 Feb; 131(3):295-300. PubMed ID: 29363644 [TBL] [Abstract][Full Text] [Related]
16. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946 [TBL] [Abstract][Full Text] [Related]
17. Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors. Breuker C; Clement F; Mura T; Macioce V; Castet-Nicolas A; Audurier Y; Boegner C; Morcrette E; Jalabert A; Villiet M; Avignon A; Sultan A Int J Cardiol; 2018 Oct; 268():195-199. PubMed ID: 30041785 [TBL] [Abstract][Full Text] [Related]
18. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Tandon N; Ali MK; Narayan KM Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes among participants with diabetes in the recent large statin trials. Armitage J; Bowman L Curr Opin Lipidol; 2004 Aug; 15(4):439-46. PubMed ID: 15243217 [TBL] [Abstract][Full Text] [Related]
20. Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence. Davidson MH J Clin Lipidol; 2010; 4(1):72-3; discussion 74. PubMed ID: 21122630 [No Abstract] [Full Text] [Related] [Next] [New Search]